Close Menu

GeneDx

The large BRCA1 deletion, which was not captured by initial genetic testing, might be the reason for the patient's exceptional response to a PARP inhibitor. 

Many companies and counselors see the COVID-19 pandemic as a catalyst for moving germline risk testing into a digital-first healthcare model.